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1097-99 Underuse of Reperfusion Therapy in Female Patients: 
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Tirofiban Versus Placebo in the Treatment of Acute 
Myocardial Infarction) 
1097-101 Glycoprotein Ilb/llla Inhibitors After Full Dose 
Thrombolysis in Rescue Angioplasty for Acute 
Myocardial Infarction: To Give or Not Give? 
Luis Gruberq, Mahmoud A. Suleiman, Michael Kapekovich, Haimm Hammerman. Ehud 
Grenadier, Monther Boulus, Walter Markiewicz, Rafael Beyar, Rambam Medical Center, 
Haifa, Israel 
Marc Cohen, Gian France Gensini, Frans Maritz, Enrique P. Gurfinkel, Kurt Huber, Ari 
Timerman. Maria Krzeminska-Pakula. Nicolas Danchin, Harvey D. White, Luc Vittori. 
MCP Hahnemann University, Philadelphia, PA 
Women have higher mortality rates following STEMI, ‘yet fewer are considered eligible for 
reperfusion therapy. The international TETAMI study was designed to asssss the effi- 
cacy and safety of antlthrombotic therapy in STEMI patients inekgible for reperfusion. 
and a concurrent registry tracked patients at the same centers which were either reper- 
fused or not reperfused and ineligible for TETAMI. 
Methods: We studied the predictors for reperfusion or non reperfusion therapy in 2542 
patients form the TETAMI study and registry. Patients with Killip class 4 were excluded. 
Endpoint data for the composite double endpoint of death 8 Ml and death alone were 
analyzed. A multivariate analysis was performed to determine the influence of age, gen- 
der, timing from symptoms to admission. Killip class 1 versus 2l3, gender and country. 
Results: Overall a higher proportion of male patients received reperfusion therapy. This 
was the case in all countries studied except South Africa. Europe had the lowest rate of 
reperfusion therapy in female patients. Male reperiused patients had the lowest rates of 
both death and death & MI. However multIvariate analysis reveals that this is accounted 
for, with a level of 5% confidence, by the greater age and later presentation of women. 
Conclusions: Multivariate analysis reveals that reperiusion therapy IS less frequently 
given to women because women are older and present to the hospital at a later stage. 
Awareness should be increased in order lo shorten this delay in presentation for women. 
Background: Percutaneous coronary intervention after failed thrombolysis (rescue angio- 
plasty) in patients with acute myocardial infarction (AMI) is an established procedure. 
Few data are available concerning the safety and efficacy of glycoprotein Ilb/llla inhlbl- 
tars in these patients. Methods: We compared the clinical outcomes of 53 consecutive 
AMI patients who underwent rescue angioplasty between 111997 and 12/2001. A total of 
24 were treated concomitantly with a glycoprotein Ilb/llla inhibitor and 29 patients were 
not. Resuks: Baseline clinical characteristics between the two groups were similar and 
comparable for all variables, with exception of a significantly larger percentage of 
patients with prior angioplasty in the llblllla group (3% vs. 28%, p=O.O4). In-hospital out- 
comes regarding major and rmnor bleedmg complications, death and urgent revascular- 
ization were similar. By multwariate analysis, no treatment with a Ilb/llla was an 
independent predictor of worse outcome (RR:7.3; CI=l.4-26.2, p=O 026). The composite 
of death, urgent revascularization and emergency bypass surgery IS shown in the Fig. 
Conclusions: Patients who undergo rescue angioplasty due to failed thrombolysis and 
are concomitantly treated with glycoprotein llblllla inhibitors are at a lower risk of in-hos- 
pltal death and repeat urgent revascularizatlon procedures. The administration of glyco- 
protein Ilb/llla inhibitors after full dose thrombolysis did not increase the risk of bleeding 
complications. 
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Taha Taher Yuling Fu, Galen S. Wagner, Shaun G. Goodman, Claudia Fresco, -I 
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We studied 4,049 patients in ASSENT 3 who received flbrinolytic therapy to evaluate the 
relationship between aborted MI (by CK), QRS score and do-day mortality. Aborted MI 
was detected [peak CK less than or equal to 2x upper normal] in, 569 patients (14.1% of 
this population). ST segments and QRS scores ware measured in four technically suit- 
able sequential ECGs (baseline, 60 and 180 minutes post thrombolylic, and discharge) 
by a core lab blinded to clinlcal outcomes. These data reveal that patients with aborted 
MI have a shorter time to treatment, higher frequency of early ST resolution and clear 
confirmatory evidence of preserved myocardium from their QRS score. An particularly 
low nsk subset within the aborted MI group i.e. the 53% of patients with >70% ST resolu- 
tion at 60 min exists whose 30 day mottality was 1.0% vs 8.1% for other aborted Ml 
patients (p=O.OOl) emphasizing the value of subset analysis. These novel observations 
provide additional insight into the process of early risk stratification following fibrinolysis 
forAMI. 
Aborted Ml 
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Age-yrs (Median:25-75%) 62 (53,71) 
Female (%) 29% 
Time to treatment (Median: hr) 2.5 (1.8, 3.5) 
>70% ST resolution 60 min 53% 
>70% ST resolution - 180 min 58% 
~70% ST resolution - D/C 74% 
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Background Primary percutaneous coronary interventcon (P-PCI) is an effective repefiu- 
sion treatment in patients (pts) with acute myocardial infarction (AMI). However, It IS 
unclear whether the outcome of pts with AMI transferred from the community hospitals to 
tertiary centers for P-PCI is different from that of pts treated with on-site P-PCI. Methods 
Data are derived from the AMI-Florence Registry, a prospective observational registry 
Including all the Florence area residents who expenenced ST-segment elevation AMI 
from 3.1.2000 to 2.28.2001 and were admitted to hospital within 12 h from symptom 
onset. Florence area includes 5 community hospitals and 2 tertiary centers with specific 
programs for P-PCI. 
Results This analysis refers lo the 432 pts treated wth P-PCI. Of these pts, 286 were 
directly admitted to the 2 centers with P-PCI facilities (Group 1) and 146 were initially 
admitted to the 5 community hospitals and then transferred to the 2 centers with invasive 
facilities (Group 2). In term of risk factors and clinical characteristics. a lower prevalence 
of prior angina was observed in Group 1 (27.7% vs 44.5%, p=.OO4); Killip Class >I was 
observed in 19% of Group 1 and 25% of Group 2 (p=.O9); cardiogenic shock was present 
in 6% of Group 1 and 5.5% of Group 2 (p=.66). Median time from symptom onset lo 
admission was 135 min in Group 1 and 121 min in Group 2; median door-to-balloon time 
was 30 min in Group 1 and 115 min in Group 2 (p=.OOl). Door-to-balloon time was < 60 
min in 81% of Group 1 and 19% of Group 2 (p=.OOOl). TIMI grade 3 flow was restored in 
95.1% of Group 1 and 93.8% of Group 2 (p=ns). Left ventricular ejection fraction at dis- 
charge was exactly the same I” both Groups (mean 45+ 12%). Six-month mortality was 
8.7% in Group 1 and 10.3% in Group 2. Comparing mortality in pts with door-to-balloon 
time 2 60 min and ~60 min. no stgnlflcant difference was observed in both patient 
Groups. Conclusion Pts transferred from hospitals without P-PCI facllitles have an out- 
coma which is similar lo the one of pts directly admitted to hospitals with P-PC1 facllitles. 
Our data support a policy of transfernng patients initially admitted to community hospitals 
to centers which offer P-PCI. 
